Welcome to our dedicated page for Bioatla SEC filings (Ticker: BCAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioAtla, Inc. (BCAB) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context to help interpret them. As a clinical-stage biotechnology company focused on Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, BioAtla uses its filings to report on financing arrangements, governance matters, clinical program updates and Nasdaq listing status.
Among the core documents, investors can review Form 8-K current reports where BioAtla describes material events such as Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide equity-linked financing, including key terms like pricing formulas, exchange caps and ownership limits. Other 8-K filings incorporate press releases detailing quarterly financial results and clinical program progress, and discuss interactions with Nasdaq’s Listing Qualifications Staff and conditions for continued listing on The Nasdaq Capital Market.
The DEF 14A definitive proxy statement offers insight into corporate actions submitted to stockholders, including proposals to approve potential issuance of 20% or more of outstanding common stock under financing agreements, authorize a reverse stock split within a specified ratio range at the board’s discretion, and permit adjournments of a special meeting to solicit additional proxies. This proxy statement also explains the rationale for these proposals in the context of Nasdaq Listing Rule 5635(d) and the company’s capital needs.
Through Stock Titan, users can quickly locate BioAtla’s 10-K annual report and 10-Q quarterly reports (when filed) to understand risk factors, detailed financial statements, research and development spending, and discussion of clinical-stage assets such as ozuriftamab vedotin (Oz-V), mecbotamab vedotin (Mec-V), BA3182 and evalstotug. Form 4 insider transaction reports, when available, can be used to track share purchases or sales by directors and officers.
Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections related to financing, listing compliance, and clinical milestones, and surface relevant passages without requiring users to read every page. Real-time updates from EDGAR ensure that new BioAtla filings, including future 8-Ks, proxy materials or registration statements, appear promptly. This combination of primary documents and AI-generated explanations helps investors, analysts and researchers follow how BioAtla’s CAB platform, capital structure and governance are reflected in its SEC reporting.
BioAtla, Inc. reports that stockholders approved an internal merger with its wholly owned subsidiary BA Merger Sub, Inc., which will include a 1-for-50 consolidation of its common stock at the merger’s effective time. The company plans to complete the merger and share consolidation as soon as Nasdaq notice requirements are satisfied.
Separately, BioAtla’s board approved 2026 cash retention bonuses for key executives in place of a regular bonus plan or salary increases. The CFO and Chief Medical Officer can each earn milestone-based bonuses tied to financial and capital raising goals in May and August 2026, while the CEO’s bonus is a single milestone-based payment tied to August 2026 objectives.
BioAtla is registering 842,440 shares of common stock to be issued to YA II PN, Ltd. pursuant to its Standby Equity Purchase Agreement dated November 20, 2025. The shares are priced at approximately $0.179 per share for total proceeds of approximately $151,000, which the company intends to use for working capital and general corporate purposes. The company expects to issue the shares on or about March 20, 2026. This prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public.
Common stock outstanding after the offering will be 82,846,317 shares. The resale and methods of sale are described in the referenced "Plan of Distribution."
BioAtla is offering 631,163 shares of common stock to YA II PN, Ltd. (Yorkville) at approximately $0.171 per share pursuant to a Standby Equity Purchase Agreement dated November 20, 2025. The total purchase price is approximately $108,000 and the company expects to issue the shares on or about March 13, 2026. This prospectus supplement also covers the resale of those shares by Yorkville to the public. Common stock outstanding after the issuance will be 81,801,593 shares. The company states it intends to use net proceeds for working capital and other general corporate purposes.
Sievers Eric reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. reported that Chief Medical Officer Eric Sievers received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units (RSUs) at no purchase price.
The RSU vests as to 25% of the shares on March 10, 2027, then 6.25% on the last day of each May, August, November, and February, subject to his continued service through each vesting date. Following this award, Sievers directly holds 598,705 shares of Common Stock.
SHORT JAY M PHD reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. CEO and director Jay M. Short received a grant of 430,000 shares of Common Stock in the form of a time-based restricted stock unit award. The award was granted at no cash cost and is structured to vest over several years.
According to the vesting schedule, 25% of the RSU is scheduled to vest on March 11, 2027, with an additional 6.25% vesting on the last day of each May, August, November and February thereafter, subject to his continued service. Following this grant, Dr. Short directly holds 2,659,603 shares of Common Stock.
The filing also lists indirect holdings in BioAtla shares held by his spouse, various 2020 irrevocable gift trusts, Capia IP, LLC and Himalaya Parent LLC. For Himalaya Parent LLC, he and his spouse act as managers and collectively make investment decisions, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
Vasquez Christian reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. Chief Financial Officer Christian Vasquez received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units. These units carry no purchase price and increase his direct holdings to 530,196 shares after the award.
The RSU grant vests over time: 25% of the shares vest on March 10, 2027, with an additional 6.25% vesting on the last day of each May, August, November, and February thereafter, as long as he remains in service through each vesting date.
BioAtla is issuing 931,032 shares of common stock to YA II PN, Ltd. under a Standby Equity Purchase Agreement dated November 20, 2025, at approximately $0.166 per share for total gross proceeds of approximately $154,000. The company expects to issue the shares on or about March 9, 2026.
The prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public. Common stock outstanding after the issuance would be 81,170,430 shares.
BioAtla, Inc. reported that Chief Executive Officer Jay M. Short, Ph.D., had 7,728 shares of common stock withheld on February 28, 2026 at $0.247 per share. According to the filing, this was a tax-withholding disposition related to the vesting and net settlement of previously reported restricted stock units, and not an open-market sale.
After this withholding, Dr. Short directly holds 2,229,603 common shares. He also has indirect ownership positions through his spouse and various entities, including the Carolyn Short 2020 Irrevocable Gift Trust, the Jay Short 2020 Irrevocable Gift Trust, Capia IP, LLC, and Himalaya Parent LLC, where he and his spouse serve as managers and disclaim beneficial ownership beyond any pecuniary interest.
BioAtla, Inc. Chief Financial Officer Christian Vasquez reported a tax-related share disposition, not an open-market sale. On the reported date, 1,802 shares of common stock at a value of $0.247 per share were withheld by the company to cover income tax obligations tied to vesting restricted stock units. After this withholding event, Vasquez directly owned 290,196 shares of BioAtla common stock. This type of Form 4 transaction reflects routine equity compensation tax settlement rather than discretionary trading in the open market.
BioAtla, Inc. reported an insider equity transaction involving its Former Chief Financial Officer, Richard A. Waldron. On February 28, 2026, 2,729 shares of common stock at $0.247 per share were withheld by the company to satisfy income tax obligations tied to vesting restricted stock units. This tax-withholding disposition is not an open-market sale, and Waldron’s directly held stake stands at 343,421 common shares after the transaction.